Plasma

What is plasma and why is it so important?

Blood is a mixture of cells (e.g. red cells, platelets, white cells) suspended in plasma. The plasma portion is about 50% of the total blood volume and contains a wide range of proteins essential to life. These proteins can be separated and purified to produce a range of stable injectable products for treatment of various diseases and trauma. These products are often lifesaving and many are included in the WHO Model List of Essential Medicines.

Examples of diseases treated with Plasma Derived Medicinal Products (PDMPs).

Please click here to access the article on “Plasma” as published in Transfusion Today in September 2017.

 

Source Plasma

Source Plasma is the liquid portion of human blood collected by a procedure known as plasmapheresis. In this procedure the donor’s blood is processed through an apheresis machine, which extracts only the plasma and returns the cellular components (red cells, platelets etc) to the donor. The use of this technique permits more frequent donation than whole blood donation without harm to the donor. The plasma collected is frozen within 2 hours and may be used for individual transfusion or as a raw material for further large-scale manufacture into Plasma Derived Medicinal Products (PDMPs).

 

Recovered Plasma

Recovered plasma is the liquid portion of anti-coagulated whole blood donations remaining after separation of the cellular components.

 

Quality of Plasma

Plasma must be of high quality for subsequent manufacture into PDMPs.

Blood/plasma donor selection, collection procedures, testing methods, donation handling, storage and transport of plasma should follow defined quality assurance procedures, the importance of which has been highlighted by international guidelines.

 

Security of Supply

Strategy for secure and sustainable plasma supply

There is a sustained increase in the global demand for Plasma Derived Medicinal Products and this is likely to continue for the foreseeable future. The raw material plasma supply to meet this need is predominantly from the US where 5% of the global population provides approximately 70% of the global plasma supply. IPFA advocates a more diversified global plasma supply to minimize the risks of product shortage resulting from US plasma supply interruption or failure. IPFA calls for National and Regional policies and strategies to promote increased plasma collection and reduction of recovered plasma wastage in other regions of the world. PDMP access and supply shortages are a critical safety factor for patients.

Please click here to access the paper “Plasma is a strategic resource” published in Transfusion 2016;56;3133-3137.